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ABSTRACT
Introduction: Twin-to-twin transfusion syndrome (TTTS) is associated with a high risk of 
perinatal mortality and morbidity if not treated. However, the optimal timing and management in 
case of early (occurring <18 weeks) TTTS has not been established yet.  Material and Methods: 
This is a systematic review and meta-analysis aiming at evaluating the outcomes of 
monochorionic diamniotic (MCDA) twin pregnancies complicated by early (i.e. before 18 weeks) 
TTTS according to different management options (expectant, laser therapy, amnioreduction or 
cord occlusion). The primary outcome was mortality, including single and double intra-uterine, 
neonatal and perinatal death. Secondary outcomes were: composite morbidity, neuromorbidity, 
respiratory distress syndrome, admission to neonatal intensive care unit, intact survival (defined as 
survival free from neurological complications) and preterm birth <32 weeks’ gestation. All 
outcomes were reviewed according to the different management options (expectant, laser therapy, 
amnioreduction or cord occlusion) and reported in the overall population of twins, and in the 
donor and recipient separately. Sub-group analysis for TTTS occurring before 16 weeks of 
gestation was performed. Random-effect meta-analyses of proportions were used to analyze the 
data. Results: Thirteen studies were included. Early TTTS occurred in 14.3% (95% CI 11.9-17.0) 
of cases. Mortality: The incidence of intra-uterine death was 19.0% (95% CI 2.6-45.5) in twins 
managed expectantly, 32.4% (95% CI 16.5-50.7) in those who received laser treatment and 12.5% 
(95% CI 4.8-23.0) in those treated with amnioreduction. The incidence of neonatal death was 
22.6% (95% CI 4.2-49.8) in twins managed expectantly, 24.7% (95% CI 0.5-80.3) in those who 
received laser and 20.2 (95% CI 5.8-43.4) in those who had amnioreduction, while it was not 
possible to compute the incidence of these outcomes in twins undergoing cord occlusion because 
of insufficient sample and lack of reporting of most of the observed outcomes. Overall, the 
incidence of perinatal death was 43.9% (95% CI 5.9-87.7) in twins managed expectantly, 47.3% 
(95% CI 21.4-70.) in those treated with laser and 28.5% in those who had amnioreduction. 
Conclusions: Twin pregnancies affected by early TTTS are at substantial risk of perinatal 
mortality and morbidity; however data comes from very small studies with high risk of selection 
bias. 
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TTTS: twin-to-twin transfusion syndrome 
Key Message: 
Perinatal mortality and morbidity are a substantial risk for twin pregnancies complicated by early 
TTTS identified from small studies. There is a need for comprehensive reporting of outcome data 










This article is protected by copyright. All rights reserved
INTRODUCTION
Twin-to-twin transfusion syndrome (TTTS) is one of the most severe complications of 
monochorionic diamniotic (MCDA) twin pregnancies, with an estimated incidence of 10-15% (1). 
Although its pathophysiology has not been fully elucidated yet, the initial process that triggers 
TTTS is thought to result from unbalanced flow across the placental inter-twin vascular 
anastomoses, causing relative hypovolemia in one twin and hypervolemia in the other (2,3). This 
results in significant adverse cardiovascular changes (3). TTTS is associated with a high risk of 
perinatal mortality and morbidity if not treated, especially when the disease occurs in previable 
gestation and fetuses who survive can experience a wide range of cardiovascular, neurological and 
developmental disorders (4). 
Timely diagnosis and treatment of TTTS are crucial in order to maximize perinatal 
outcome. TTTS is classically diagnosed in the second trimester with 
oligohydramnios/polyhydramnios sequence. Dekoninck et al. (5) have shown that the amniotic 
fluid volume varies according to gestational age, providing a rationale to lower cut-off values in 
order to diagnose polyhydramnios and consequently recognize TTTS at earlier gestational ages. 
The outcomes of MCDA twin pregnancies complicated by early TTTS are likely to be worse than 
those presenting at a later gestation. The evidence is controversial, with some researchers have 
reported similar mortality to TTTS presenting at a later stage (6). Moreover, the diagnostic criteria 
for polyhydramnios (deepest vertical pocket ≥ 8cm) currently used to diagnose TTTS are probably 
underestimating TTTS at earlier gestational age. These cases might also have worse outcomes due 
to the fact that they are not diagnosed as TTTS according to the current diagnostic criteria and, 
therefore, they are not offered prenatal intervention (7)..   
The introduction of laser therapy of placental anastomoses in clinical practice has led to a 
significant reduction in perinatal mortality and neurological morbidity in twin pregnancies 
complicated by TTTS (8). Conversely, occlusion of the umbilical cord may represent an option in 
case of brain abnormalities or severe growth restriction of one twin, especially when far from 
viability, with the purpose of improving the outcome of the surviving twin (9). The current 
evidence does not support the practice of amnioreduction as a first line treatment in pregnancies 
complicated by TTTS (4). In general, an overall survival rate of 50-70% can be expected after 
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Several factors influence the outcome of twin pregnancies complicated by TTTS, including 
advanced Quintero stage, fetal growth restriction and early gestational age at treatment and 
preterm birth (PTB) (11, 12). Studies have reported conflicting results on the perinatal outcomes 
of twin pregnancies complicated by early TTTS. Baud et al. (13) have reported that double 
intrauterine demise occurs in 13%, livebirth was achieved in 75% while the incidence of PPROM 
was 38%. However, the corresponding figures in the study by Lecointre et al. (6) were 36%, 55% 
and 9%, respectively
Despite its importance, there is no robust data yet on the actual risk of perinatal mortality 
and morbidity or on the optimal management of TTTS according to the gestational age at 
presentation. Therefore, the aim of this systematic review was to explore the outcome of twin 
pregnancies complicated by early TTTS.
MATERIAL AND METHODS
Protocol, eligibility criteria, information sources and search
This review was performed according to a priori designed protocol recommended for systematic 
reviews and meta-analysis. Medline, Embase, Clinicaltrials.gov and Cochrane Library databases 
were searched electronically in January 2019, utilizing combinations of the relevant medical 
subject heading (MeSH) terms, key words, and word variants for “twin pregnancies” and 
“transfusion” (Supporting Information Table S1). The search and selection criteria were restricted 
to English language. Reference lists of relevant articles and reviews were hand searched for 
additional reports. PRISMA (14) and MOOSE (15) guidelines were followed. The study was 
registered with the PROSPERO database (Registration number: CRD42019122948).
Study selection, data collection and data items
We considered for inclusion all studies (cohort studies, case series and randomized controlled 
trials if available) reporting data on outcomes of twin pregnancies affected by early (i.e. before 18 
weeks) TTTS. Types of interventions evaluated were: expectant management, selective fetoscopic 
laser ablation of vascular anastomoses, amnioreduction (with or without septostomy) and selective 
fetal reduction (by intrafetal laser or radiofrequency ablation). 









This article is protected by copyright. All rights reserved
1) Intra-uterine death (IUD) of either twin, defined as fetal loss after 20 weeks’ gestation
2) Single IUD
3) Double IUD 
4) Neonatal death, defined as the death of either twin up to 28 days of life
5) Perinatal death (PND), defined as IUD and neonatal death
The secondary outcomes were:
1) Overall neonatal morbidity, defined as the presence of at least one among: abnormal brain 
imaging, respiratory distress syndrome (RDS), admission to the neonatal intensive care unit 
or retinopathy of prematurity (ROP) in either twin
2) Neuromorbidity: defined as the presence of either intra-ventricular hemorrhage (IVH) or 
periventricular leukomalacia (PVL) of any type on post-natal imaging (ultrasound or 
magnetic resonance imaging)
3) Severe neuromorbidity, defined as the presence of either severe intraventricular 
leukomalacia (grade III and IV) or periventricular leukomalacia (grade II and III)
4) RDS
5) Admission to neonatal intensive care unit
6) Intact survival, defined as survival free from neurological complications
7) PTB <32 weeks of gestation
Two authors (CB, FGS) reviewed all abstracts independently. Agreement regarding potential 
relevance was reached by consensus; full text copies of those papers were obtained and the same 
two reviewers independently extracted relevant data regarding study characteristics and pregnancy 
outcomes. Inconsistencies were discussed by the reviewers and consensus reached or by 
discussion with a third author (FDA). If more than one study was published on the same cohort 
with identical endpoints, the report containing the most comprehensive information on the 
population was included to avoid overlapping populations. For those articles in which information 
was not reported but the methodology was such that this information would have been recorded 
initially, the authors were contacted.
Difference between protocol and review
Our review differed from our planned review because we could not assess some outcomes. In 
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studies included in the meta-analysis. Similarly, data on gestational age at delivery (absolute 
value) and premature rupture of the membranes were not consistently reported in studies or not 
reported at all. We decided to report the outcome "preterm birth" as PTB < 32 weeks because the 
data could be retrieved from a larger number of studies and is of clinical significance to 
distinguish between early PTB versus late preterm and term birth. 
Moreover, we could not perform a subgroup analysis by disease stage because some studies were 
published before Quintero's staging system (11) was adopted or authors did not report the disease 
stage.    
Planned subgroup analysis
All these outcomes were explored according to whether the management adopted (expectant, 
fetoscopic laser therapy, amnioreduction or selective reduction by intrafetal laser or 
radiofrequency ablation).  Furthermore, we aimed to report all the outcomes in the donor and 
recipient twin separately. For the purpose of the analysis, studies on amnioreduction alone and 
those on amnioreduction associated with septostomy were considered in the same group. The 
reason for this choice was based upon the fact that perinatal survival has been reported to be 
similar in pregnancies treated with amnioreduction alone compared to septostomy in either twin.
Quality assessment of the included studies
Quality assessment of the included studies was performed using the Newcastle-Ottawa Scale 
(NOS) for case-control or cohort studies. According to NOS, each study is judged on three broad 
perspectives: the selection of the study groups; the comparability of the groups; and the 
ascertainment of outcome of interest. Assessment of the selection of a study includes the 
evaluation of the representativeness of the exposed cohort, selection of the non-exposed cohort, 
ascertainment of exposure and the demonstration that the outcome of interest was not present at 
the start of study. Assessment of the comparability of the study includes the evaluation of the 
comparability of cohorts based on the design or analysis. Finally, the ascertainment of the outcome 
of interest includes the evaluation of the type of the assessment of the outcome of interest, length 
and adequacy of follow-up. According to NOS a study can be awarded a maximum of one star for 
each numbered item within the Selection and Outcome categories. A maximum of two stars can be 
given for Comparability (16). Case series were evaluated with a modified version of NOS, which 









This article is protected by copyright. All rights reserved
(Supporting Information Table S2). Although a formal score could be assigned giving a binary 
response to each question, the numeric representation of methodology quality was not considered 
appropriate and, as suggested by the authors, the overall final judgment was made based on 
questions 1, 2, 3, 7 and 8 as deemed most critical in this specific clinical scenario (17)  .
Statistical analyses 
We performed random-effect meta-analyses of proportions to estimate the pooled rates of each 
outcome in all the pregnancies and then according to the type of management reported (expectant, 
laser or selective reduction). Between study heterogeneity between study was explored using the 
I2 statistic, which represents the percentage of between-study variation that is due to heterogeneity 
rather than chance. A value of 0% indicates no heterogeneity is observed while values >50% are 
associated with substantial heterogeneity. However, a random effects model was used for all meta-
analyses because of the clinical heterogeneity identified between studies (18)..  Potential 
publication bias was assessed using Egger’s test and the creation of funnel plots for visual 
inspection (19). Tests for funnel plot asymmetry were not used when the total number of 
publications included for each outcome was less than ten, as the tests then lack power to detect 
real asymmetry (20). StatsDirect 3.0.171 (StatsDirect Ltd, Altrincham) and RevMan 5.3 (The 




A total of 1649 articles were identified, 346 were assessed with respect to their eligibility for 
inclusion (Supporting Information Table S3) and 13 studies (6,13, 21-31) were included in the 
systematic review (Table 1, Figure 1). These 13 studies included 729 twin pregnancies affected by 
TTTS. TTTS occurred at ≤18 weeks’ gestation in 14.3%, (95% CI 11.9-17.0; 104/729), and for 
3.0% (95% CI 2.0-4.5; 22/729) the onset was at ≤16 weeks of gestation. Among the included 
studies, three reported the outcome of twin pregnancies affected by early TTTS in case of 
expectant management, 5 that of laser treatment of placental anastomoses, 8 that of 
amnioreduction and one that of cord occlusion. Four studies reported on more than one modality: 
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The results of the quality assessment of the included studies using NOS or its modified version are 
presented in Table 2. Most of the included studies showed an overall good score regarding the 
selection and comparability of the study groups, and for ascertainment of the outcome of interest 
while case-series were scored low-quality. The main weaknesses of these studies were their 
retrospective design, small sample size and different gestational ages at intervention..
Mortality
The incidence of IUD was 19.0% (95% CI 2.6-45.5) in the MCDA twin pregnancies with TTTS 
which were managed expectantly, 32.4% (95% CI 16.5-50.7) in those who had laser treatment, 
and 12.5% (95% CI 4.8-23.0) in those who had amnioreduction. Only one study reported the 
outcome of twins affected by early TTTS and treated with cord occlusion. This study included 
only one case and reported that cord occlusion was followed by the death of the co-twin (Table 3, 
Figure 2).
The incidence of neonatal death was 22.6% (95% CI 4.2-49.8) in twins managed expectantly, 
24.7% (95% CI 0.5-80.3) in those who had laser and 20.2 (95% CI 5.8-43.4) in those who had 
amnioreduction.  No studies have reported outcomes in twin survivor who had cord occlusion of 
other co-twin (Table 3). Overall, the incidence of PND was 43.9% (95% CI 5.9-87.7) in twins 
managed expectantly, 47.3% (95% CI 21.4-70.) in those treated with laser and 28.5% in those who 
had amnioreduction.
The incidence of single IUD was 0% (95% CI 0-25.8) in twins managed expectantly, 14.8% (95% 
CI 8.4-22.7) in those who had laser and 13.7% (95% CI 5.8-24.4) in those who had 
amnioreduction, while there was no information on the incidence of such outcomes in twins 
managed with cord occlusion. Conversely, double IUD occurred in 19.0% (95% CI 2.6-45.5) of 
twins managed expectantly, 15.8% (95% CI 9.2-23.8) of those treated with laser and 7.3% (95% 
CI 1.8-16.1) of those who had amnioreduction (Table 3).
When exploring the occurrence of IUD in the donor and recipient twin separately, IUD occurred in 
28.0% (95% CI 0.02-79.3) of cases both in the donor and recipient twin managed expectantly and 
in 24.1% (95% CI 12.8-37.6) and 30.9% (95% CI 18.4-45.1) of those who had laser therapy, in 
17.4% (95% CI 5.2-34.8) and 10.4% (95% 1.6-25.4) of donor and recipient twin, respectively, in 
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Likewise, PND occurred in 54.0% (95% CI 11.4-93.2) of cases in the donor and recipient twin 
managed expectantly, in 37.7% (95% CI 11.2-68.9) of donors and 27.4% (95% CI 4.2-61.2) of 
recipients who had laser and in 30.5% of donors and 25.5% of the recipients who had 
amnioreduction.
Preterm birth, morbidity and intact survival
PTB occurred in 74.1% (95% CI 36.9-97.8) of pregnancies managed expectantly, 43.5% (95% CI 
26.5-51.3) of those treated with laser and in 65.3% (95% CI 45.8-80.7) of those who had 
amnioreduction, while the only case treated with cord occlusion gave birth before 32 weeks of 
gestation. Ascertainment of the risk of morbidity was affected by the very small number of 
included studies; only one study included 3 cases for which they reported information on 
morbidity in twins affected by early TTTS treated with laser. Likewise, the only study on cord 
occlusion did not report information of morbidity. Therefore, the figures for morbidity were 
reported only for twins managed expectantly or who had amnioreduction (Table 3).
Composite perinatal morbidity, defined as the diagnosis of any morbidity as listed before, 
occurred in 31.2% (95% CI 17.8-75.4) of twins managed expectantly and 50.7% (95% CI 29.4-
71..8) of those who had amnioreduction. The incidence of the different morbidities in twins 
affected by early TTTS according to the management option and disease status (donor vs 
recipient) are reported in Table 3.
Ascertainment of intact survival, defined as survival free from neurological complications, was 
also challenging. The analysis was limited by the very small number of included cases. 
Furthermore, there was no study on twins affected by early TTTS managed expectantly and who 
had cord occlusion which explored such outcomes. In twins who had amnioreduction, 51.9% (95% 
CI 32.3-71.2) of cases did not have any neurological complication after birth, while all twins 
treated with laser had intact survival although only three cases were included for this outcome 
(Table 3). 
Sub-group analysis: TTTS ≤16 weeks of gestation
Sub-analysis including cases affected by TTTS ≤16 weeks of gestation was limited by the small 
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robustness of the results. The data on the different outcomes explored in MCDA twin pregnancies 
complicated by early TTTS ≤16 weeks of gestation are reported in Table 4.
Sub-group analysis: TTTS >18 weeks of gestation
In order to compare outcomes for early and late (>18 weeks) TTTS that received a similar 
management, we performed a subgroup-analysis including cases affected by late TTTS (i.e. more 
than 18 weeks) from the included studies, as shown in Supporting Information Table S4.  
The incidence of IUD was 19.9% (95% CI 7.8-35.7) after expectant management, 17% (95% CI 
2.3-41.3) and 12.5% (95% CI 6.7-19.9) after laser and amnioreduction respectively. When 
exploring the occurrence of neonatal death, this was similar in expectancy and amnioreduction, i.e. 
29.5% and 23.8% respectively and lower after laser therapy (7.6%). Overall, the incidence of PND 
was 46.7% (95% CI 29.4-64.4) in twins managed expectantly, 34.2% (95% CI 25.3-61.5) in those 
treated with laser and 35.6% in those who had amnioreduction. The other outcomes are presented 
in Table S4. 
DISCUSSION
The findings from this systematic review show that twin pregnancies complicated by early TTTS 
are at increased risk of perinatal mortality and morbidity. The incidence of PND was 43.9% in the 
twin pregnancies which were managed expectantly, 47.3% in those treated with laser and 28.5% in 
those who had amnioreduction, while no data could be extrapolated on cord occlusion.
Composite perinatal morbidity, occurred in 31.2% of twins managed expectantly and 50.7% of 
those who had amnioreduction. PTB occurred in 74.1% of pregnancies managed expectantly, 
43.5% of those treated with laser and in 65.3% of those who had amnioreduction. 
Cases of TTTS after 18 weeks from the same studies were complicated by PND in 46.7% of cases 
after expectant management, 34.1% and 35.6% after laser and amioreduction respectively. PTB 
complicated 52.1% and 51.8% after expectancy and amnioreduction respectively and 34.2% after 
laser treatment. 
This is, to our knowledge, the first systematic review exploring the outcome of pregnancies 
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relevant studies, multitude of outcomes explored and stratification of the analysis according to the 
type of prenatal management adopted are the main strengths of this systematic review. 
The small number of cases in some of the included studies, their retrospective non-randomized 
design, lack of standardized criteria for the antenatal surveillance and management of MCDA twin 
pregnancies complicated by early TTTS and therefore the overall low quality of many of them 
represent the major limitations of this systematic review. Assessment of the potential publication 
bias was also problematic because of the nature of the outcome evaluated (outcome rates, with the 
left-side limited to a value of zero), which limits the reliability of funnel plots, and the scarce 
number of individual studies, which strongly limits the reliability of formal tests. 
Another major limitation of the present systematic review was the lack of stratification of the 
results according to the ultrasound staging of the disease. In MCDA pregnancies, TTTS can be 
classified in five stages based on findings from two-dimensional ultrasound and Doppler 
velocimetry in the umbilical artery, vein, and ductus venosus. Recent evidences suggest that the 
first stage of the disease in MCDA twins, characterized by the presence of 
oligohydramnios/polyhydramnios sequence on ultrasound, is associated with a better prognosis 
(32, 33). However, the small number of included studies did not allow performing this subgroup 
analysis. Sub-group analysis considering the type of prenatal management was also limited by the 
very small number of included cases and even smaller number of events, thus affecting the 
robustness of the results. Furthermore, the large majority of cases included in the expectant 
management studies came from old studies carried out before the Eurofetus trial was published, 
thus making it not feasible to perform a comprehensive comparison with the outcomes observed in 
more recent publications This is the reason why we did a sub-group analysis of late TTTS (>18 
weeks) from the studies included in this meta-analysis and reported these data in Table S4.  
Finally, subgroup analysis including only cases treated before 16 weeks of gestation was hindered 
by the even smaller number of included cases, and therefore, we could not stratify the analysis 
according to other pregnancy characteristics such as the disease stage or placental position. 
Despite these limitations, the present review represents the most comprehensive published 
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TTTS is one of the major determinants of perinatal outcome in MCDA twin pregnancies (3). 
Introduction of laser therapy in clinical practice over the last two decades has significantly 
modified the natural history of this disease (34). Perinatal survival of fetuses with TTTS has been 
reported to be around 65% in recent non-randomized large series (8).  In the present systematic 
review, PND complicated 47.3% of fetuses affected by early TTTS. These figures suggest a 
relatively higher risk of death in twin pregnancies affected by early TTTS. A likely explanation for 
such phenomenon might be that early TTTS represents a more severe spectrum of the disease. 
Another explanation could be the prolonged exposure to the fetuses to the massive hemodynamic 
changes, which occur in TTTS in case of early disease. In this scenario, early TTTS may represent 
a peculiar clinical phenotype of the disease characterized by a more pronounced cardiovascular 
derangements leading to a higher risk of adverse perinatal outcome. Likewise, the high rate of 
PTB observed in these pregnancies could account for the increased risk of PND reported in the 
present review. 
Amnioreduction does not represent the first line therapy for TTTS as laser treatment has been 
shown to be associated with a higher perinatal survival in the Eurofetus trial (35), although it may 
represent an option in case of TTTS stage 2 or higher in conditions where transfer to a centre that 
performs laser therapy is not possible (36). Survival rates of about 50% have been reported 
following amnioreduction (37). However, such practice, especially when repeated, is associated 
with a high risk of PTB and does not alter the natural history of the disease. Overall, the survival 
rates after amnioreduction have been reported to be around 50% in the published literature, 
irrespective of the stage and gestational age at onset of the disease. In the present systematic 
review, PND occurred in 34% of pregnancies affected by early TTTS while PTB complicated 66% 
of cases. The high incidence of PTB observed in the present review is likely to be the consequence 
of the need for repeated procedures and does not support a policy of amnioreduction in 
pregnancies affected by early TTTS. In fact, although the results suggest a relatively lower PND 
rate compared to the group managed with laser therapy, these groups are not comparable, since 
expectant management and/or amnioreduction may be chosen for milder forms of the disease but 
also when laser was not available, in order to alleviate maternal symptoms due to polyhydramnios, 
or to reduce the risk of PTB or a mix of these reasons, introducing a selection bias. This is an 
inherent bias associated with most of the observational studies. Moreover, data on amnioreduction 
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treatment is associated with higher survival rates (38) and a reduction in the risk of long-term 
major neurological impairment at the age of 5 years (39). 
The most interesting and challenging group is represented by very early cases, when TTTS occurs 
before 16 weeks. In this group the diagnosis is still a challenge and the Quintero staging system is 
not applicable. In fact, clinicians often diagnose TTTS at this early gestation based on other 
features such as oligohydramnios (stuck twin) with amniotic fluid discordance, distended bladder 
with/without abnormal fetal Dopplers with/without tricuspid regurgitation or cardiomegaly and 
with a deep vertical pocket (DVP of ≥6 cm) in the larger twin. This is why new cut-off values for 
DVP are proposed before 18 weeks, lowering the DVP cut-off of diagnosing polyhydramnios to 6 
cm (7,11)
Another challenging query is whether laser treatment before 16 weeks increases the chances of 
preterm prelabour rupture of membranes (PPROM) and therefore it might be better to postpone 
laser therapy after 16 weeks’ gestation, or whether using equipment, such as embryoscope or 
smaller fetoscope, it is as safe as performed after 16 weeks. We tried to answer this question but 
data on these pregnancies are very limited (only 14 pregnancies treated with laser and 7 treated 
with amnioreduction). Data regarding the PPROM rates <7 days after laser were reported in 13/14 
pregnancies with an incidence of 23.1% (3/13). Furthermore, only two studies (3 pregnancies) 
reported this data after amnioreduction precluding any conclusion. The question regarding the 
higher chance of PPROM cannot be truly answered, however the high rates of PTB (69%) seem to 
indicate that postponing laser therapy after 16 weeks might be a reasonable option.   
 
Interruption of the blood flow in the umbilical cord through radiofrequency ablation or bipolar 
umbilical cord coagulation represents an effective procedure when one fetus is severely 
jeopardized and delivery is not yet an option, in order to maximize the outcome of the surviving 
twin (40). In the present review, we could not consistently report the incidence of perinatal 
mortality in twin pregnancies complicated by TTTS undergoing cord occlusion in view of the very 
small number of included cases and lack of ascertainment of most of the observed outcomes. The 
current practice includes that cord occlusion should not be offered as the first line treatment in 
case of early TTTS unless there is imaging evidence of major fetal compromise such as severe 
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In the present systematic review, we could not systematically report objective data on morbidity in 
twin pregnancies affected by early TTTS. One of the major challenges in ascertaining the outcome 
of MCDA twin pregnancies complicated by TTTS is the wide heterogeneity in outcomes 
definition, post-natal assessment and time at follow up. Furthermore, the large majority of 
previously published studies focused on mortality while there is a generically lack of data on 
morbidity. This may be partially explained by the fact that TTTS is a condition associated with a 
very high risk of mortality if untreated. Therefore, the majority of published studies focused on 
mortality. However, with an improving rate of survival, there is now need for objective data on 
short- and long-term morbidities in order to be able to provide the relevant outcomes data which 
the parents need before making an informed decision. We have recently published the core 
outcome set in TTTS (41), aiming to improve the quality of reporting future studies.
CONCLUSION
Twin pregnancies complicated by early TTTS are at substantial risk of perinatal mortality and 
morbidity. However, in view of the small number of included cases, heterogeneity in outcome 
definition, reporting and time at follow-up, the present review does not allow us to extrapolate an 
objective evidence on the optimal prenatal management in these pregnancies. Future studies using 
standardized definitions and objective protocols of prenatal diagnosis and management, including 
post-natal follow-up, are needed in order to provide more accurate estimates of the clinically 
relevant perinatal outcomes. This should enable us to provide better individualized counselling 
and optimal management of twin pregnancies complicated by early TTTS.
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Table S1. Search strategy.
Table S2: Tool for evaluating the methodological quality of case reports and case series** (15).










Table S4: Pooled proportions for the incidence of the different adverse outcomes explored in the present 
review in monochorionic diamniotic (MCDA) twin pregnancies complicated by TTTS diagnosed at or 
beyond 18 weeks of gestation.
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Table and figure legends
Table 1. General characteristics of the included studies.
Table 2 - Quality assessment of the included studies according to Newcastle–Ottawa Scale 
(NOS)*or to modified Newcastle-Ottawa, Pierson and Bradford Hill scales for case series**.
Table 3: Pooled proportions (PP) for the incidence of the different adverse outcomes explored in the present 
review in monochorionic diamniotic (MCDA) twin pregnancies complicated by early TTTS.
Table 4: Pooled proportions for the incidence of the different adverse outcomes explored in the present 
review in monochorionic diamniotic (MCDA) twin pregnancies complicated by early TTTS occurring 
before 16 weeks of gestation.
Figure 1 - Flow chart illustrating identification of studies included in this systematic review.
*some studies reported on more than one management.
Figure 2 – Graphical representation of the Pooled proportions for the incidence of perinatal death 
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Table 1. General characteristics of the included studies 
 







Cases affected by 
early (<18 weeks) 
TTTS (n) 
Cases affected by 
very early (<16 





















USA Retrospective Case series NS 19 5 1 Amnioreduction, 
Expectant 
Mortality, Obstetric, 











Turkey Retrospective Case series 1999-2002 17 4 2 Amnioreduction, 
Expectant 
Mortality, Obstetric, 






















































UK Prospective Case-control 
study 










Germany Prospective Case-control 
study 
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Table 2 - Quality assessment of the included studies according to Newcastle–Ottawa Scale (NOS)*or to 
modified Newcastle-Ottawa, Pierson and Bradford Hill scales for case series**. 
 





2013 ★★★ ★★ ★★★ 
Blaicher
19
** 2002 Low quality 
Dennis
20
** 1997 Low quality 
Elliott
21
** 1991 Low quality 
Has
22
** 2005 Low quality 
Johnson
23
* 2001 ★★ ★ ★★ 
Lecointre
5
* 2014 ★★★ ★★ ★★★ 
Lim
24
** 2005 Low quality 
Mahieu-Caputo
25





2000 Low quality 
Sebire
27
* 1998 ★ ★ ★★★ 
Sepulveda
28
** 2007 Low quality 
Willruth
29
* 2013 ★★ ★ ★★ 
 
 
* Cohort/Case-control studies assessed according to Newcastle-Ottawa Scale (NOS) (assessment based on 
selection/comparability/exposure-outcome. Highest scores are 4 for selection, 2 for comparability and 3 for 
exposure-outcome) (14). 
**Case series/reports assessed with a tool that published at BMJ Evidence-Based-Medicine Journal on April 
2018 (Supplementary Table 2). Authors specifically mention about not to use an aggregate score for this tool on 
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Table 3: Pooled proportions (PP) for the incidence of the different adverse outcomes explored in the present review in monochorionic diamniotic (MCDA) 
twin pregnancies complicated by early twin to twin transfusion syndrome. 
 
Outcome Studies (n) 
 Expectant management  Laser therapy  Amnioreduction  Cord occlusion 


















IUD (overall) 3,4,7,1   2/10 19.00 
(2.6-45.5) 
76.5  27/92 32.39 
(16.5-50.7) 
27.8  6/48 12.46 
(4.8-23.0) 
0  1/1 100 
(2.5-100) 
- 
Single IUD 3,4,7,1  0/10 0 (0-25.8) 0  13/92 14.82 
(8.4-22.7) 
0  4/48 13.73 
(5.8-24.4) 
0  - - - 
Double IUD 3,4,7,1  2/10 19.00 
(2.6-45.5) 
76.5  14/92 15.83 
(9.2-23.8) 
0  2/48 7.31 
(1.8-16.1) 
0  - - - 
IUD donor 3,3,6,0  1/5 27.97  
(0.02-79.3) 
44.8  10/43 24.12  
(12.8-37.6) 
0  3/23 17.41 
(5.2-34.8) 
0  - - - 
IUD recipient 3,3,6,0  1/5 27.97  
(0.02-79.3) 
44.8  13/43 30.92 
(18.4-45.1) 
0  1/23 10.40 
(1.6-25.4) 
0  - - - 
                  
NND (overall) 3,3,7,0  2/10 22.56 
(4.2-49.8) 
0  2/12 24.68 
(0.5-80.3) 
77.9  8/48 20.14 
(5.8-43.4) 
53.1  - - - 
Single NND 3,3,7,0  0/10 0 (0-25.8) 0  0/12 0 (0-22.5) 0  2/48 7.43 
(1.9-16.3) 
0  - - - 
Double NND 3,3,7,0  2/10 15.36 
(12.9-40.7) 
0  2/12 24.68 
(0.5-80.3) 
77.9  6/48 14.75 
(1.7-37.5) 
66.8  - - - 
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(2.2-63.1) (7.2-73.0) (3.0-29.4) 
NND (recipient) 3,3,6,0  1/5 25.88 
(2.2-63.1) 
0  1/6 24.08 
(7.2-73.0) 
48.4  4/24 20.80 
(7.3-38.9) 
1  - - - 
                  
PND (overall) 3,4,7  4/10 43.90 
(5.9-87.0) 
58.4  21/60 47.32 
(21.4-70.0) 
57.1  14/48 28.47 
(17.1-41.4) 
44.5  1/1 100 
(2.5-100) 
- 
Single PND 3,4,7  0/10 0 (0-25.8) 0  9/60 16.07 
(8.1-26.2) 
0  2/48 7.13 
(1.8-15.7) 
0  - - - 
Double PND 3,4,7  4/10 43.90 
(5.9-87.0) 
  12/60 28.92 
(6.7-58.8) 
64.2  12/48 24.79 
(14.1-37.4) 
40.4  - - - 
PND donor 2,3,7  2/4 53.99 
(11.4-93.2) 
13.2  10/27 37.66 
(11.2-68.9) 
29.9  6/21 30.51 
(13.6-50.7) 
4.7  - - - 
PND recipient 2,3,7  2/4 53.99 
(11.4-93.2) 
13.2  7/27 27.34 
(12.9-44.9) 
39.4  5/21 25.46 
(10.4-44.4) 
0  - - - 
                  
Preterm birth 
PTB <32 weeks 3,5,8,1  4/5 74.12 
(36.9-97.8) 
0   30/70 43.53 
(26.5-61.3) 
35.6  16/25 65.25 
(45.8-80.7) 
2.7  1/1 100 
(2.5-100) 
- 





2,1,4,0  2/6 31.24 
(17.8-75.4) 
31.8  0/3 0 
(0-70.8) 
-  9/18 50.67 
(29.4-71.8) 
0  - - - 
Composite 
morbidity 
2,1,3,0  1/3 35.49 
(2.2-81.7) 
0  0/1 0 
(0-97.5) 
-  4/7 56.91 
(24.6-86.2) 
















2,1,3,0  1/3 35.49 
(2.2-81.7) 
0  0/1 0 
(0-97.5) 
-  3/7 40.81 
(12.2-73.4) 
57.6  - - - 
                  
Neuromorbidity 
(overall) 
1,1,20  0/2 0 
(0-84.2) 
-  0/3 0 
(0-70.8) 
-  3/10 32.40 
(14.8-53.1) 
0  - - - 
Neuromorbidity 
(donor) 
1,1,0,0  0/1 0 
(0-97.5) 
0/1  0/1 0 
(0-97.5) 
-  - - -  - - - 
Neuromorbidity 
(recipient) 
1,1,0,0  0/1 0 
(0-97.5) 
0/1  0/1 0 
(0-97.5) 
-  - - -  - - - 




1,1,1,0  0/2 0 
(0-84.2) 
-  0/3 0 
(0-70.8) 
-  1/4 25.00 
(0.6-80.6) 




1,1,0,0  0/1 0 
(0-97.5) 
0/1  0/1 0 
(0-97.5) 




1,1,0,0  0/1 0 
(0-97.5) 
0/1  0/1 0 
(0-97.5) 
-  - - -  - - - 
                  
RDS (overall) 0,1,1,0  - - -  0/3 0 
(0-70.8) 
-  3/6 50.00 
(11.8-80.6) 
-  - - - 
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(0-97.5) 
RDS (recipient) 0,1,0,0  - - -  0/1 0 
(0-97.5) 
-  - - -  - - - 




2, 1,3,0  0/6 0 
(0-34.6) 
0  0/3 0 
(0-70.8) 
-  8/12 65.64 
(39.3-87.6) 








 0/1 0 
(0-97.5) 
-  3/8 39.49 
(11.9-71.4) 




2,1,2,0  0/3 0 
(0-34.6) 
0  0/1 0 
(0-97.5) 
-  3/8 39.49 
(11.9-71.4) 




0,1,2,0  - - -  3/3 100 
(29.-100) 
-  12/23 51.89 
(32.3-71.2) 
74.0  - - - 
Intact survival 
(donor) 
0,0,2,0  - - -  2/2 100 
(15.8-100) 
-  5/11 33.10 
(0.1-89.0) 
75.1  - - - 
Intact survival 
(recipient) 
0,0,2,0  - - -  1/1 100 
(2.5-100) 
-  7/12 57.64 
(31.0-82.1) 
 
0  - - - 
 
a: analysis not computed because the studies with information on the occurrence of IUD in the donor and recipient twin did not report any IUD. 
missing values are due to the fact that some fetuses underwent TOP. 
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Table 4: Pooled proportions for the incidence of the different adverse outcomes explored in the present review in monochorionic diamniotic 
(MCDA) twin pregnancies complicated by early twin to twin transfusion syndrome occurring before 16 weeks of gestation. 
 
Outcome Studies (n) 
 Expectant management  Laser therapy  Amnioreduction  Cord occlusion 






















IUD (overall) 1,3,4,0  0/2 0 
(0-84.2) 
-  12/28 52.79 
(19.5-84.7) 
67.4  1/16 11.10 
(1.2-29.2) 
0  - - - 
Single IUD 1,3,4,0  0/2 0 
(0-84.2) 
-  4/28 24.21 
(0.4-679) 
79.9  1/16 0 
(0-21.7) 
0  - - - 
Double IUD 1,3,4,0  0/2 0 
(0-84.2) 
-  8/28 27.93 
(3.3-64.2) 
70.3  1/16 11.10 
(1.2-29.2) 
0  - - - 
IUD donor 1,2,4,0  0/1 0 
(0-97.5) 
-  6/13 46.49 
(22.0-71.9) 
0  1/8 19.17 
(2.0-47.8.7) 
0  - - - 
IUD recipient 1,2,4  0/1 0 
(0-97.5) 
-  4/13 34.26 
(3.2-76.9) 
63.8  0/8 0 
(0-32.7) 
0  - - - 
                  
NND (overall) 1,2,4,0  0/2 0 
(0-84.2) 
-  1/18 8.67 
(0.5-25.0) 
0  2/16 12.55 
(1.7-31.2) 
33.9  - - - 
Single NND 1,2,4,0  0/2 0 
(0-84.2) 
-  1/18 8.67 
(0.5-25.0) 
0  0/16 0 
(0-19.3) 
0  - - - 
Double NND 1,2,4,0  0/2 0 
(0-84.2) 
-  0/18 0 
(0-13.2) 
0  2/16 12.55 
(1.7-31.2) 
33.9  - - - 
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(0-97.5) (1.0-43.7) (1.2-44.3) 
NND (recipient) 1,2,4,0  0/1 0 
(0-97.5) 
-  0/9 0 
(0-24.1) 
0  1/8 16.51 
(1.2-44.3) 
0  - - - 
                  
PND (overall) 1,2,4,0  0/2 0 
(0-84.2) 
-  7/18 40.65 
(20.2-62.9) 
73.4  3/16 21.16 
(6.0-42.4) 
0  - - - 
Single PND 1,2,4,0  0/2 0 
(0-84.2) 
-  5/18 29.52 
(11.7-51.4) 
81.7  1/16 11.10 
(1.2-29.2) 
0  - - - 
Double PND 1,2,4,0  0/2 0 
(0-84.2) 
-  2/18 13.81 
(2.4-32.4) 
0  2/16 13.94 
(0.7-40.0) 
33.9  - - - 
PND donor 1,1,4,0  0/1 0 
(0-97.5) 
0/1  4/8 50.00 
(15.7-84.3) 
-  2/8 17.01 
(3.7-37.2) 
0  - - - 
PND recipient 1,1,4,0  0/1 0 
(0-97.5) 
0/1  1/8 12.50 
(0.3-82.7) 
-  1/8 9.26 
(0.6-26.5) 
0  - - - 
                  
Preterm birth 
PTB <32 weeks 1,3,4,0  1/1 100 
(25.0-100) 
0  9/14 63.13 
(38.5-84.6) 
0  3/8 40.55 
(13.8-70.8) 
0  - - - 





1,0,2,0  0/2 0 
(0-84.2) 
-  - - -  3/6 50.48 
(18.9-86.2) 
67.2  - - - 
Composite 
morbidity 
1,0,2,0  0/1 0 
(0-97.5) 
0/1  - - -  2/3 64.51 
(18.3-97.8) 
















1,0,120  0/1 0 
(0-97.5) 
0/1  - - -  1/3 35.49 
(2.2-81.7) 
0  - - - 
                  
Neuromorbidity 
(overall) 
1,0,0,0  0/2 0 
(0-84.2) 
-  - - -  - - -  - - - 
Neuromorbidity 
(donor) 
1,0,0,0  0/1 0 
(0-97.5) 
0/1  - - -  - - -  - - - 
Neuromorbidity 
(recipient) 
1,0,0,0  0/1 0 
(0-97.5) 
0/1  - - -  - - -  - - - 




1,0,0,0  0/2 0 
(0-84.2) 




1,0,0,0  0/1 0 
(0-97.5) 




1,0,0,0  0/1 0 
(0-97.5) 
0/1  - - -  - - -  - - - 
                  
RDS (overall) 0,0,0,0  - - -  - - -  - - -  - - - 
RDS (donor) 0,0,0,0  - - -  - - -  - - -  - - - 
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1,0,1,0  0/2 0 
(0-84.2) 
0/1  - - -  2/2 100 
(15.8-100) 




1,0,1,0  0/1 0 
(0-97.5) 
0/1  - - -  1/1 100 
(25.0-100) 




1,0,1,0  0/1 0 
(0-97.5) 
0/1  - - -  1/1 100 
(25.0-100) 




0,0,2,0  - - -  - - -  6/10 56.54 
(11.2-95.6) 
65.3  - - - 
Intact survival 
(donor) 
0,0,2,0  - - -  - - -  2/5 35.23 
(0.2-88.8) 
53.7  - - - 
Intact survival 
(recipient) 
0,0,2,0  - - -  - - -  4/5 77.32 
(28.6-99.9) 
37.5  - - - 
Missing values are due to the fact that some fetuses underwent TOP. 
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